Review Article
Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials
Table 2
Overview of number of studies and patients available for primary and secondary analyses.
| | Progression-free survival | Overall survival |
| Primary endpoint | trials ( pts) | trials ( pts) |
| Secondary endpoint: PFS/OS subgroup analyses | | | Gender (male/female) | = 4 trials ( = 3,017 pts) | = 3 trials ( = 2,651 pts) | Age (cut-off 65 years) | = 4 trials ( = 2,835 pts) | = 3 trials ( = 2,651 pts) | ECOG status (0 versus ≥1) | = 4 trials ( = 2,825 pts) | = 3 trials ( = 2,641 pts) | KRAS status (WT/MUT) | = 4 trials ( = 2,545 pts) | = 3 trials ( = 2,417 pts) |
| Secondary endpoint: remission/progression analyses | | Remission rate | = 5 trials ( = 3,199 pts) | Progression rate | = 4 trials ( = 2,826 pts) | Prevention of progression rate | = 4 trials ( = 2,652 pts) |
|
|